Clinical questions & evidence
Evidence-based answers to clinical questions about EEG-derived biomarkers, cue-induced craving, and their role in substance use disorder (SUD) and opioid use disorder (OUD) care. Each page provides a direct answer, supporting evidence, and clinical interpretation grounded in published research. All biomarker-based tools referenced are investigational.
- What EEG-derived ERP/VEP biomarkers are most predictive of relapse risk in substance use disorders?Cluster: Biomarkers & Measurement
- How can cue-reactivity biomarkers support assessment / clinical decision support (CDS) in OUD care?Cluster: Clinical Decision Support (OUD/SUD)
- How is neurofeedback used to reduce cue-induced craving in opioid and other substance use disorders?Cluster: Neurofeedback & Treatment Implications
- What is the difference between self-reported craving and biomarker-based craving assessment?Cluster: Biomarkers & Measurement
- How does cue-induced craving appear in EEG/ERP measurements?Cluster: Biomarkers & Measurement
- What is the evidence that cue-induced craving predicts relapse outcomes in substance use disorders?Cluster: Biomarkers & Measurement
- How should clinicians interpret changes in craving biomarkers across treatment?Cluster: Clinical Decision Support (OUD/SUD)
- Which patients are most appropriate for EEG-based craving assessment in clinical or research settings?Cluster: Clinical Decision Support (OUD/SUD)
Looking for term definitions? See Terminology & definitions for Neurotype, NeuromarkR™, and Modit™.
